Of 15 patients followed at least six months, 10 had no progression or death on Zai Lab's drug combo.
Zai Lab's drug combo, zoci plus atezolizumab, showed an 81.8% response rate and 81.9% 6-month progression-free survival in extensive-stage small-cell lung cancer (ES-SCLC) patients. 66.7% of 15 patients had no progression or death after six months. The treatment was well-tolerated, with Grade 3+ adverse events in 9.1% of patients. Zai Lab plans to initiate a global Phase 3 trial by year-end 2026.
How this was made
The 30-second read
Why it matters
The data represent the first public disclosure of efficacy signals for zoci, a key milestone before a global Phase 3 trial, likely influencing investor sentiment and valuation.
Market read
Positive early trial results could drive Zai Lab's share price higher and impact the broader oncology biotech sector.
What to watch
Regulatory timelines and potential competition from other DLL3‑targeting agents could temper upside.
Background
Zai Lab (NASDAQ: ZLAB) announced early clinical data for its DLL3‑targeting ADC zoci combined with atezolizumab, showing high response rates in extensive‑stage small‑cell lung cancer.
Ticker impact
Zai Lab disclosed early Phase 1/2 data showing 81.8% response rate and durable responses for its zoci ADC in extensive-stage small-cell lung cancer.
likely upward pressure as market prices in the strong efficacy and safety signals.
First disclosure of high response rates and durable outcomes for a novel ADC; biotech stocks typically react positively to such data.
Market effects
Strengthens the outlook for ADC platforms and small-cell lung cancer therapeutics, potentially benefiting peers in oncology biotech.
May lift Chinese‑listed biotech sentiment and US‑listed biotech ADRs.
Adds to the pipeline narrative for novel oncology agents, relevant to global oncology investors.
Counterpoint
Skeptics may question durability of responses and the lack of comparative data versus standard chemo‑IO regimens.
Key entities
- CompanyZai Lab Limited
Biopharma developing zoci ADC for small‑cell lung cancer.
- DrugAtezolizumab
PD‑L1 inhibitor combined with zoci in the trial.
